Chicago's VA hospital enrolls its first veterans in a psilocybin-assisted therapy program, expanding access to an experimental mental health treatment

Veterans at a Chicago VA hospital have begun enrolling in a psilocybin-assisted therapy program aimed at addressing serious mental health conditions through a closely supervised psychedelic treatment model. The initiative marks a notable step for a major veterans' care institution as interest grows in psilocybin for depression, PTSD, and related disorders. Psilocybin-assisted therapy typically combines screening, preparation, monitored dosing sessions, and integration support rather than relying on the drug alone. Clinical momentum around this approach has been driven by early research suggesting potential benefits for treatment-resistant conditions, though the therapy remains experimental and tightly regulated. A VA-linked program matters because veterans experience elevated rates of trauma-related distress, depression, and suicidality, while many patients do not respond fully to standard care. Hospital-based enrollment signals gradual mainstream movement from research settings toward structured medical access, even as safety protocols, evidence standards, and federal policy barriers continue to shape what is possible.